Masimo Corp. ( (MASI) ) has released its Q2 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Masimo Corporation is a global medical technology company specializing in innovative monitoring technologies, including pulse oximetry, sensors, and patient monitors, primarily serving the healthcare sector with a focus on improving patient outcomes and reducing care costs.
In its second quarter of 2025, Masimo Corporation reported strong financial results, showcasing significant growth in both revenue and earnings. The company achieved a GAAP revenue of $371 million, marking an 8% increase, and a non-GAAP net income per diluted share of $1.33, reflecting a 46% growth compared to the previous year.
Key highlights from the earnings report include a robust performance in Masimo’s core healthcare business, driven by strategic efforts to enhance its market position in pulse oximetry and advanced monitoring solutions. The company also successfully implemented tariff mitigation measures, reducing the expected impact by 50%, and expanded its leadership team to support its growth strategy.
Looking ahead, Masimo’s management remains optimistic, projecting non-GAAP revenue growth of 8% to 11% for the full year 2025, with an expected operating profit ranging from $406 to $440 million. The company continues to invest in its core healthcare business to sustain its growth momentum and potentially accelerate long-term revenue growth.